Ajax-Loading

Merck & Company Inc - Price To Sales Ratio

Merck & Company Inc's Fiscal Year is From January To December.

The item "Price-To-Sales-Ratio" stands at 2.67 as of 09/30/2025, the lowest value at least since 06/30/2022, the period currently displayed.

As of the end of Merck & Company Inc's third quarter, the item "Price To Sales Ratio" stands at 2.67. This represents a decrease of -6.91 percent compared to it's value at the end of it's second quarter .


Regarding the One-Year-Change of the series, the current value constitutes a decrease of -34.08 percent compared to the value the year prior.
The 1 year change in percent is -34.08.
The 3 year change in percent is -15.25.

The Serie's long term average value is 3.67. It's latest available value, on 09/30/2025, is 27.24 percent lower, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is +0.0%.
The Serie's change in percent from it's maximum value, on 03/31/2024, to it's latest available value, on 09/30/2025, is -44.43%.

Price To Sales Ratio for Related Companies:

LogoNameMarket Cap (USD)
LogoEli Lilly and Company - Price To Sales Ratio905,699,262,464.00
LogoJohnson & Johnson - Price To Sales Ratio486,508,953,600.00
LogoAbbVie Inc - Price To Sales Ratio399,570,305,024.00
LogoRoche Holding AG - Price To Sales Ratio317,433,206,677.55
LogoAstraZeneca PLC - Price To Sales Ratio280,205,508,085.11